Colombia — registered products & how Taj Pharma should operate (GMP-compliant, practical playbook)

Below I explain (1) the Regulatory landscape for registering medicines in Colombia, (2) the technical dossier / GMP / PV expectations (what INVIMA will look for), (3) practical operational steps Taj Pharma must take to commercialize products in Colombia (based on your Table 1 product list), and (4) a concise action checklist and recommended documentation bundle. I cite INVIMA and recent regulatory summaries for the most important points.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
Sitagliptin + Metformin Hydrochloride—AntidiabeticTablets (Box of 30)100 mg + 1000 mgClass III
Sitagliptin + Metformin Hydrochloride—AntidiabeticTablets (Box of 30)50 mg + 1000 mgClass III
Sitagliptin Phosphate USP—AntidiabeticTablets (Box of 30)100 mgClass III
Sitagliptin Phosphate USP—AntidiabeticTablets (Box of 30)50 mgClass III
Sacubitril / Valsartan—Cardiovascular (Heart Failure)Tablets (Box of 30)49 mg + 51 mgClass II
Sacubitril / Valsartan—Cardiovascular (Heart Failure)Tablets (Box of 30)97 mg + 103 mgClass II
Dapagliflozin—Antidiabetic (SGLT2 Inhibitor)Tablets (Box of 30)10 mgClass III
Sofosbuvir + Velpatasvir—Antiviral (HCV)Tablets (Box of 30)400 mg + 100 mgClass I

1) Snapshot — regulator & key rules

  • The national regulator is INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos). All sanitary registrations (registros sanitarios) for medicines and biologics are issued by INVIMA and submissions must follow INVIMA formats and be in Spanish.
  • INVIMA requires a full product dossier for a marketing authorisation (quality / CMC, manufacturing, stability, clinical or bioequivalence data as applicable), proof of GMP for the manufacturing site, lab testing data (COAs, chromatograms), labeling in Spanish, and an appointed local legal representative / MAH for Colombia.
  • Typical regulatory timelines vary depending on route (fast-track vs conventional) and product type — published analyses indicate fast/accelerated reviews can be ~6–10 months, while conventional pathways may take 12–24 months (historical ranges). INVIMA has also run temporary contingency measures to accelerate backlog clearance (e.g., March 2025 plan). Use these windows for planning.

2) What INVIMA expects — dossier & GMP (detailed)

These are the load-bearing dossier elements INVIMA will review for each medicine from your Table 1 (e.g., digoxin, dofetilide, atomoxetine, vonoprazan, carbamazepine ER, etc.):

A. Administrative & legal

  • Application form + proof of fee payment (in pesos).
  • Power of attorney / legal representation in Colombia (MAH or local authorised representative).
  • Certificate of Pharmaceutical Product (CPP) may be required especially if product is new to Colombia or for originator biologics.

B. Quality / CMC dossier

  • Complete drug master file: composition (Q&Q), manufacturing process, in-process controls, specification and release tests, analytical methods and validation, reference standards, packaging materials and labels (Spanish).
  • Batch Certificates of Analysis (COAs) for representative industrial batches, stability data supporting claimed shelf life under ICH/INVIMA conditions, and accelerated/real-time stability reports where required.

C. GMP evidence

  • Valid GMP certificate for the manufacturing site(s). INVIMA accepts certificates issued by competent authorities and recognized references; in many cases an INVIMA inspection may be requested or the authority may rely on inspections from recognized regulators (PIC/S relationships and mutual recognition matter). Ensure the GMP certificate is current and that QA/GMP documents (GMP certificate + latest inspection report, corrective actions) are available.

D. Clinical / BE requirements

  • For new chemical entities or novel formulations, clinical data or bridging studies may be required. For generics, INVIMA typically requires proof of bioequivalence when the product is not in the national pharmacopoeia or depending on equivalence status — expect BE studies or accepted waivers per INVIMA guidance.

E. Labelling and leaflet

  • Primary/secondary packaging artwork and Patient Information Leaflet in Spanish, with required mandatory statements, storage conditions, and local symbols.

F. Pharmacovigilance (PV)

  • Marketing Authorisation Holders (MAHs) must have an active pharmacovigilance system. Recent 2024–2025 updates require appointment of a local licensed PV contact (doctor or pharmacist resident in Colombia), maintenance of a Spanish PSMF (Pharmacovigilance System Master File) and submission of periodic safety reports (PSUR/ICSRS per INVIMA timelines). INVIMA can request PSMF and PV evidence at any time.

3) How Taj Pharma should operate in Colombia — practical, GMP-first approach

Below is an operational blueprint that keeps Taj Pharma compliant and speeds approvals for the products listed in your Table 1.

A — Market entry model (recommended)

  1. Local MAH / Distributor: Appoint a Colombia-based legal entity (subsidiary, branch, or an established local distributor) to act as the MAH. This person/entity handles registrations, import permits, pharmacovigilance obligations, and local regulatory correspondence. INVIMA requires a local representative.
  2. Registration strategy by product bucket:
    • High-priority / flagship products (e.g., unique molecules like vonoprazan, dofetilide if marketable): submit full dossiers first using accelerated/faster channels where applicable.
    • Well-established generics (e.g., fluoxetine, propranolol, furosemide): pursue generic pathway with BE waivers or standard BE studies depending on INVIMA guidance and the national pharmacopoeia listings.
    • Specialty / high-value (e.g., tapentadol combos, atomoxetine, acitretin): ensure strong CMC and PV readiness pre-submission.

B — GMP & Quality operations

  1. GMP certification readiness: maintain up-to-date GMP certificate that is acceptable to INVIMA. If Taj’s manufacturing sites are inspected by WHO, EU, FDA, or a PIC/S authority, include inspection reports and corrective action documentation. Where possible, obtain a Certificate of Pharmaceutical Product (CPP) from the country of origin regulator to support dossier.
  2. Local QC & batch release: coordinate with a Colombia-based QC lab if INVIMA requires local testing or a GLP/INVIMA-recognised QC lab certificate. Keep full COA history and retained samples per INVIMA guidance.

C — Regulatory submission & timelines

  1. Complete Spanish dossier (translate all technical documents and artwork to Spanish). Include full CMC, validation, stability, GMP, COAs, and legal documents.
  2. Expect timelines: plan for 6–24 months depending on the pathway: fast/contingency tracks may reduce time; conventional reviews longer. Factor in time for QA responses, local inspections, and PV setup.

D — Pharmacovigilance & post-marketing

  1. Local PV contact: appoint a licensed physician or pharmacist resident in Colombia as the Qualified Person for PV (LPPV). Maintain a Spanish PSMF, routine expedited reporting for ICSRs, and periodic safety reports. INVIMA’s recent updates emphasize active local PV presence.
  2. Post-market surveillance: implement product complaint handling, local AE intake (Spanish-speaking), and periodic reporting. Keep batch traceability and be ready for pharmacovigilance inspections.

E — Import, logistics & commercial considerations

  • Customs & sanitary import permit (permiso sanitario de importación): coordinate with MAH/distributor to obtain sanitary import permits and ensure shipments include CPP, GMP and COAs.
  • Labelling, serialization & anti-counterfeiting: ensure pack artwork meets INVIMA labelling law — include Spanish safety statements, registration number once issued, storage conditions, and batch/expiry clear printing.
  • Pricing & reimbursement: Colombia has its own pricing and procurement mechanisms (public tenders, POS lists). Market access teams will be needed to map tender opportunities and hospital formulary listings.

4) Suggested Documentation & Submission Checklist (ready for each product)

  1. Cover letter + application form (Spanish)
  2. Proof of fee payment (copy of bank receipt).
  3. Power of Attorney + MAH appointment documents (local rep).
  4. Full CMC dossier (Q&Q, manufacturing description, process validation, specifications, analytical methods + validation).
  5. Batch COAs (3 production batches recommended) + chromatograms.
  6. Stability data supporting shelf-life (ICH/real time and accelerated).
  7. GMP certificate for manufacturer + inspection reports / corrective action plan.
  8. CPP (if available) and marketing history in other countries.
  9. Label artwork and PIL in Spanish.
  10. Pharmacovigilance documentation: PSMF (Spanish), local PV contact details, SOPs for AE handling.
  11. BE study reports (if applicable) or rationale for BE waiver.
  12. Any additional clinical/efficacy documentation if the product is new to the Colombian market.

5) Timelines & cost signals (planning numbers)

  • Regulatory approval time: plan 6–24 months (fast-track/programs may compress to ~6–10 months; conventional may take 12–24 months). Build regulatory buffer.
  • Government fees: official INVIMA fees vary by product type; summaries indicate application fees in the range of millions of COP (examples: ~11.6–18.7 million COP for chemical medicines, higher for biologics) — confirm on submission. Budget also for translations, local representative fees, PV setup, and potential local testing.

6) Practical risks and mitigations

  • Risk — GMP gaps or expired certificates: Mitigation: maintain continuous GMP compliance, keep inspection reports, and have corrective actions documented.
  • Risk — Spanish translation / technical mismatch: Mitigation: use experienced Spanish regulatory writers; pre-validate translated analytical methods with local lab if needed.
  • Risk — PV non-compliance: Mitigation: appoint local PV contact, maintain a Spanish PSMF and AE reporting SOPs.

7) Suggested immediate next steps for Taj Pharma (actionable)

  1. Decide MAH model: set up a local MAH or appoint a reputable Colombian distributor with regulatory experience.
  2. Prioritise product list from Table 1 into: (A) fast track (novel/specialty), (B) standard generic, (C) low priority.
  3. GMP dossier audit: perform a gap assessment of Taj’s manufacturing sites against INVIMA expectations and ensure valid GMP certificates and inspection records.
  4. Prepare Spanish dossier templates (CMC, stability, COAs, artwork) and a standard PV package (PSMF + local PV contact).
  5. Budget & timeline: allocate ~6–24 months per dossier depending on route; include local filing and translation costs, PV setup, local testing contingency, and application fees.

Key references (selected)

  • INVIMA official portal — procedures and requirements.
  • Freyr: “Key requirements for INVIMA approval” (GMP, CPP, dossier components).
  • INVIMA pharmacovigilance guidance (PSMF / PSUR requirements).
  • Lexology summary (fee ranges and regulatory notes — illustrative fee guidance).
  • U.S. Trade/market intelligence on INVIMA contingency plans (March 2025 acceleration).

 PLANTILLA — LISTA DE VERIFICACIÓN DEL EXPEDIENTE (DOSSIER) PARA REGISTRO SANITARIO – INVIMA

(Aplicable para un producto – Formato estándar Taj Pharma India Ltd.)

1. Información Administrativa

1.1. Nombre del Producto (DCI):
[Especificar]

1.2. Marca Comercial (si aplica):
[Especificar]

1.3. Forma Farmacéutica:
[Especificar]

1.4. Concentración(es):
[Especificar]

1.5. Titular del Registro (MAH):
Taj Pharma India Ltd.
Plot No. 1019, Vill. Sarigam, G.I.D.C., Road No. 10,
Dist. Valsad, Gujarat, India – 396155
Certificaciones: WHO-GMP, ISO 9001:2018, PIC/S, GLP

1.6. Representante Legal en Colombia (si aplica):
[Nombre de la empresa/local MAH]
[Dirección]
[Persona de contacto]
[Correo electrónico / Teléfono]

1.7. Fabricante del Producto (Sitio Principal):
Taj Pharma India Ltd.
Plot No. 1019, Vill. Sarigam, G.I.D.C., Road No. 10,
Dist. Valsad, Gujarat, India – 396155
Certificaciones: WHO-GMP, ISO 9001:2018, PIC/S, GLP

1.8. Fabricante de Principio Activo (API):
[Nombre del fabricante del API]
[Dirección completa]
[Certificaciones GMP]

1.9. Forma de Participación:
☐ Fabricante
☐ Importador
☐ Empaquetador secundario (si aplica)

1.10. Documentos Administrativos Incluidos:
☐ Formulario de solicitud (INVIMA)
☐ Comprobante de pago de tasas
☐ Poder / Carta de Representación
☐ Certificado de Producto Farmacéutico (CPP)
☐ Declaraciones / Cartas de compromiso aplicables

2. Documentación de Calidad (Módulo CMC – Completo)

2.1. Fórmula Cualitativa y Cuantitativa (Q&Q)

☐ Detallada por unidad de dosificación
☐ Justificación de excipientes
☐ Monografías aplicables

2.2. Descripción del Proceso de Manufactura

☐ Diagrama de flujo
☐ Controles en proceso (IPC)
☐ Parámetros críticos
☐ Validación de proceso (3 lotes)

2.3. Especificaciones del Producto Terminado

☐ Pruebas de identificación
☐ Ensayo (potencia)
☐ Impurezas / productos de degradación
☐ Disolución / uniformidad
☐ Contenido de humedad
☐ Límite microbiano (cuando aplique)

2.4. Método Analítico y Validaciones

☐ Procedimientos analíticos completos
☐ Validaciones (exactitud, precisión, linealidad, especificidad, robustez)
☐ Registros de calibración del laboratorio

2.5. Certificados de Análisis (COA)

☐ 3 lotes industriales del producto terminado
☐ COA del API
☐ Cromatogramas anexos

2.6. Estabilidad

☐ Estudios acelerados (6 meses)
☐ Estudios a largo plazo (12–24 meses)
☐ Condiciones ICH Zona IVB (Clima Tropical: 30°C/75% HR)
☐ Justificación de vida útil propuesta
☐ Estabilidad en envase final

3. Información del Producto (Rotulado y Empaque)

☐ Arte final del empaque primario (blíster, frasco, ampolla, jeringa)
☐ Arte final del empaque secundario
☐ Información en español conforme INVIMA
☐ Condiciones de almacenamiento
☐ Número de lote, fecha de fabricación y vencimiento
☐ Inserto / Prospecto para el paciente (PIL) en español
☐ Advertencias obligatorias según categoría farmacológica

4. Estudios Clínicos / Bioequivalencia

☐ Reporte completo de estudio de Bioequivalencia (si aplica)
☐ Sinopsis del protocolo
☐ Reporte estadístico
☐ Certificación GLP del centro
☐ Justificación de exención de BE (cuando corresponda)
☐ Evidencia de utilización del producto en otros países (si se requiere)

5. Seguridad – Farmacovigilancia

5.1. Sistema Maestro de Farmacovigilancia (PSMF)

☐ PSMF en idioma español
☐ Estructura del sistema PV global de Taj Pharma
☐ Flujo de comunicación para reporte de eventos adversos
☐ Procedimientos escritos (SOPs) para PV
☐ Gestión de señales y manejo de riesgos

5.2. Persona Responsable de PV en Colombia (QPPV/LPPV)

Nombre: _______________________
Profesión: Médico / Farmacéutico
Correo electrónico: __________________
Teléfono: __________________

5.3. Reportes y Cumplimiento

☐ Procedimientos para reporte de ICSRs
☐ PSUR / PBRER (cuando aplique)
☐ Integración con sistemas corporativos Taj Pharma

6. Información Regulatoria Adicional

☐ Certificaciones GMP vigentes (Taj Pharma y terceros)
☐ Auditorías / Reportes de inspección recientes
☐ Plan de continuidad del suministro
☐ Contratos con terceros (API, empacado, laboratorio)
☐ Declaración de cumplimiento con guías ICH e INVIMA
☐ Justificación de categoría del producto (RX/OTC/controlado)

7. Anexos del Expediente

☐ Carta de estabilidad
☐ Carta de compromiso de lotes comerciales
☐ Estudios de compatibilidad
☐ Bosquejos de etiquetas
☐ Certificados de materiales de empaque
☐ Seguridad ocupacional del API (SDS/MSDS)

 Resumen de Verificación (Checklist Final)

ÍtemCompletadoObservaciones
Documentos Administrativos☐
Módulo CMC (Calidad)☐
Estabilidad☐
Bioequivalencia / Clínicos☐
Rotulado Español☐
PV / PSMF☐
GMP / Inspecciones☐
Anexos☐

Firma del Responsable del Dossier

Nombre: __________________________________
Cargo: ____________________________________
Fecha: _____________________________________